Læknaneminn - 01.04.2004, Side 58

22. Wu C, Zhou D, Wen C, Zhang L, Como P, Qiao Y, Relationship between blood
pressure and Alzheimer's disease in Linxian County, China. Life Sci 2003 Jan 24;
72(10):1125-33.
23. de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci
2002 Nov; 977:196-215.
24. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med
2002; 34(5):357-79.
25. Mayeux R., Sano M. Drug Therapy: Treatment of Alzheimer's Disease. N Engl
J Med 1999;341:1670-1679.
26. Michaelis ML, Drugs Targeting Alzheimer's disease: Some things old and some
things new, J Pharmacol Exp Ther 2003 Mar;304(3):897-904,
27. Jón Snædal. Fyrirlestur um Alzheimerlyf. 2003.
Url: http://www.hi.is/pub/liflyfjafr/jonsnaedal/kennsla-lae-Alz.ppt
28. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC,
Maud CM, Engelbrecht I, Hock C, leni JR, Bahra RS. A multinational, randomised,
12-week, comparative study of donezepil and rivastigmine in patients with mild to
moderate Alzheimer's disease. Int J Clin Pract 2002; 56(6):441-6.
29. Lilienfeld S. Galantamine - a novel cholinergic drug with a unique dual mode
of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev
2002 Summer; 8(2); 159-76.
30. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database
Syst Rev 2002;(3):CD001747
31. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholineesterase inhibitors
in the treatment of neuropsychiatric symptoms and functional impairment in
Alzheimer disease: a meta-analysis. JAMA 2003 jan 8; 289(2):210-16.
32. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment
of dementia. Int J Clin Pract Suppl 2002 jun;(127):45-63.
33. JannMW,ShirleyKL,SmallGW.CIinicalpharmacokineticsandpharmacodynamics
of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41 (10):719-39
34. Areosa SA, Sheriff F. Memantine for dementia. Cochrane Database Syst Rev
2003;(1 ):CD003154.
35. Url: http://www.memantine.com/inhalte/s1.html (Engar uppl. um höf. texta)
36. Hartmann S, Mobius HJ. Tolerability of memantine in combination with
cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003 Mar;
18(2):81 -5.
37. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA. Mitochondrial
involvement in Alzheimer's disease. Biochim Biophys Acta 1999; 1410; 171 -82.
38. Rogers J, Lue L-F, Brachova L, Webster S, Schultz J: Inflammation as a
response and a cause of Alzheimer’s pathophysiology.Dementia 1995; 9:133
-138.
39. Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM:
Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue
of patients with Alzheimer's disease.Am J Pathol 1994; 144:104 -116.
40. Prasad KN, Hovland AR, La Rosa FG, Hovland PG: Prostaglandins as putative
neurotoxins in Alzheimer's disease.Proc Soc Exp Biol Med 1998; 219:120-125.
41. Zandi PP, Breitner JCS. Do NSAIDs prevent Alzheimer's disease? And, if so,
why? The epidemiological evidence. Neurobiology of aging 2001; 22(6):811-17.
42. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as
possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic
studies. Neurology 1996; 47:425 -432.
43. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and
the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen
Psychiatry 1998; 55:809-815.
44. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s
disease in womenAm J Epidemiol 1994; 140:256-261.
45. Fillit HM. The role of hormone replacement therapy in the prevention of
Alzheimer disease. Arch Intern Med 2002; 162(17):1934-42.
46. Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer’s
disease: the story so far. Drugs Aging 2002; 19(6):405-27.
47. Mulnard RA, Cotman CW, Kawas CW, et al. Estrogen replacement therapy for
treatment of mild to moderate Alzheimer disease: a randomized controlled trial.
JAMA 2000; 283:1007-1015.
48. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's
disease in women: randomized, double-blind, placebo-controlled trial. Neurology
2000; 54:295-301.
49. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and
cerebral blood flow in AD: a controlled study. Neurology 2000; 54:20612066.
50. Burns M, Duff K. Cholesterol in Alzheimer's disease and taopathy. Ann N Y
Acad Sci 2002 Nov; 977:367-75.
51. Wolozin B. CYP46 (24S-cholesterol hydroxylase) a genetic risk factor for
Alzheimer disease. Arch Neurol 2003 Jan; 60(1 ):16-8.
52. Papassotiropoulos A, Streffer J, Tsolaki M, et al.lncreased brain b-amyloid load,
phosphorylated tau, and risk for Alzheimer disease, associated with an intronic
Cyp46 polymorphism. Arch Neurol 2003; 60:29-35.
53. Wolozin B. Cholesterol and Alzheimer’s disease. Biochem Soc Trans 2002
Aug; 30(4):525-9.
54. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane
Database Syst Rev 2001; (4):CD003160.
55. Austen B, Christodoulou G, Terry JE. Relation between cholesterol levels,
statins and Alzheimer's disease in the human population. J Nutr Health Aging
2002; 6(6):377-82.
56. Schenk D, et al. Immunization with amyloid-attenuates Alzheimer-disease-like
pathology in the PDAPP mouse. Nature 1999; 400:173-177.
57. Bard F, et al. Peripherally administered antibodies against amyloid b-peptide
enter the central nervous system and reduce pathology in a mouse model of
Alzheimer’s disease. Nature Med 2000; 6:916-919.
58. Holzman DM, Bales KR, Paul SM, DeMattos. Ab-immunization and anti-Ab
antibodies: potential therapies for the prevention and treatment of Alzheimer
disease. Adv Drug Deliv Rev 2002; 54(12);1603-13.
59. Sigurdsson EM, ScholtzovaH, MehtaP, Frangione B, WisniewskiT. Immunization
with a nontoxic/nonfibrillar amyloid b homologous peptide reduces Alzheimer's
disease associated pathology in transgenic mice. Am J Pathol 2001; 159:439-
447.
60. DeMattos RB, Bales KR, Cummings DJ, Dodart JC, Paul SM, Holtzman DM.
Peripheral anti-Ab antibody alters CNS and plasma clearance and decreases brain
Ab burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA
2001;98:8850-8855.
61. Dominguez Dl, De Strooper B. Novel therapeutic strategies provide the real
test for the amyloid hypothesis of Alzheimer’s disease. Trends Pharmacol Sci 2002
Jul; 23(7):324-30.
62. Lai EC. Notch Cleavage: Nicastrin helps presenilin make the final cut. Curr Biol
2002 Mar 19; 12(6):R200-2.
63. Helmuth L. New Alzheimer's treatments that may ease the mind. Science 2002
Aug 23; 297(5585): 1260-2.
64. Iwata N, et al. Identification of the major Ab1-42 degrading catabolic pathway
in brain parenchyma: suppression leads to biochemical and pathological deposition.
NatMed 2000; 6:143-150.
65. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and
other metallopeptidases? J Neurochem 2002 Apr; 81 (1 ):1 -8.
66. R.A. Cherny et al. Treatment with a copper-zinc chelator markedly and rapidly
inhibits b-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron
2001;30:665-676.
67. Selkoe DJ. Deciphering the genesis and fate of amyloid b-protein yields novel
therapies for Alzheimer disease. J Clin Invest 2002; 110:1375-1381
Heimildir af fylgiskjölum:
69. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical
diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group
under the auspices of Department of Health and Human Services Task Force on
Alzheimer’s Disease. Neurology 1984;34:939-944.
70. Knopman DS, Knapp MJ, Gracon Sl, Davis CS. The Clinician Interview-Based
Impression (CIBI); a clinician’s global change rating scale in Alzheimer's disease.
Neurology 1994;44:2315-2321.
58-Læknaneminn 2004